Lonza Group (FRA:LO3) Other Financing: €520 Mil (TTM As of Dec. 2025)


FRA:LO3 Lonza Group Ltd FRA:LO3
81 GF Score
Price €614.00
GF Value €642.72
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Lonza Group Other Financing?

Lonza Group FRA:LO3 +0.66% 81 Other Financing is €520 Mil as of Dec. 2025. GuruFocus rates FRA:LO3 with a GF Score™ of 81/100 and a GF Value™ of €642.72 (Fairly Valued). The stock has 3 warning signs investors should review.

Lonza Group's Other Financing for the six months ended in Dec. 2025 was €230 Mil.

Lonza Group's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was €520 Mil.

Lonza Group Other Financing Historical Data

* Premium members only.

The historical data trend for Lonza Group's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lonza Group Other Financing Chart

Lonza Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 333.44 209.76 516.40 484.14 521.90

Lonza Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 167.54 333.64 140.31 289.99 230.41
FRA:LO3
81GF Score
Lonza Group Ltd FRA:LO3
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lonza Group Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €520 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of €520 Mil mean?
Lonza Group (FRA:LO3) has a Other Financing of €520 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Lonza Group and its competitors.
Is Lonza Group's Other Financing too high?
Lonza Group's current Other Financing is €520 Mil. Overall, Lonza Group has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Other Financing compare to TMO and DHR?
Lonza Group's Other Financing of €520 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Medical Diagnostics & Research company?
A good Other Financing depends on the Medical Diagnostics & Research industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Lonza Group and its competitors. Lonza Group's current Other Financing is €520 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (FRA:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €642.72, compared to a current price of €614.00 — trading 4.5% below its estimated fair value. The current Other Financing is €520 Mil. Lonza Group's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Lonza Group (FRA:LO3), the current Other Financing is €520 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lonza Group (FRA:LO3) Overvalued in 2026?

Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued. The current stock price of €614.00 is trading 4.5% below its estimated GF Value™ of €642.72. GuruFocus considers Lonza Group to be Fairly Valued.

Key valuation signals for FRA:LO3:

  • Other Financing: €520 Mil
  • GF Value™: €642.72 vs. price of €614.00 (4.5% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the FRA:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lonza Group Business Description

Address Muenchensteinerstrasse 38, Basel, CHE, 4002
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
81GF Score

Get the complete analysis for FRA:LO3

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€614.00
Price
€642.72
GF Value